{
    "nct_id": "NCT04435600",
    "official_title": "A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis",
    "inclusion_criteria": "* Diagnosis of chronic plaque psoriasis for at least 6 months before the Baseline Visit.\n* Stable severe or moderate to severe plaque psoriasis as defined in each study part by body surface area (BSA) psoriasis involvement and scores on the Psoriasis Area and Severity Index (PASI) and Static Physician Global Assessment (sPGA).\n* Candidate for systemic therapy as assessed by the investigator and meet the disease activity criteria at both the Screening and Baseline Visits per the protocol.\nHealthy volunteers allowed\nMust have minimum age of 6 Years\nMust have maximum age of 17 Years",
    "exclusion_criteria": "- Concurrent clinically significant medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the participant's participation in this study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk by participating in the study.",
    "miscellaneous_criteria": ""
}